Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Herent – page 128

1 979 clinical trials in Herent, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Herent at a glance
1 979
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 979 trials in Herent

Open in trial search

Colitis ulcerative+2

Not recruiting

Study on Subcutaneous Infliximab for Patients with Ulcerative Colitis, Crohn's Disease, or Unclassified Inflammatory Bowel Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Belgian IBD Research and Development

Prostate cancer

Not recruiting

Study of Stereotactic Body Radiotherapy with or without Darolutamide for Patients with Oligorecurrent Prostate Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Universitair Ziekenhuis Gent

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide
  • Sponsor:Takeda Development Center Americas Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on the Safety and Effects of BNT314 Alone or with Pembrolizumab for Patients with Advanced Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BNT314
  • Sponsor:BioNTech SE

Study on Zanubrutinib for Patients with Primary Cold Agglutinin Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Plasma cell myeloma

Not recruiting

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alnuctamab
  • Sponsor:Celgene International II S.a.r.l.

Study of Farletuzumab Ecteribulin vs. Chemotherapy for Women with Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Bristol Myers Squibb International Corporation

Cervix carcinoma

Not recruiting

Study on Tisotumab Vedotin, Bevacizumab, Carboplatin, and Pembrolizumab for Patients with Recurrent or Stage IVB Cervical Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Herent

What the registry says about research in the country

01 Immunology Research

Ongoing clinical research focusing on SARS-CoV-2 immunity in diverse population groups, investigating antibody responses and immune system functionality in both healthy individuals and immunocompromised patients.

  • Antibody Response Monitoring
  • Variant of Concern Studies
  • Immunocompromised Population Research

This longitudinal study examines immune responses in nursing home residents, dialysis patients, and transplant recipients, providing crucial data for understanding long-term immunity patterns.

02 Transplant Medicine

Specialized investigation of COVID-19 immunity in kidney and lung transplant patients, focusing on their unique immune responses and vulnerability to viral infections.

  • Post-Transplant Immunity
  • Infection Risk Assessment
  • Antibody Development Patterns

The research aims to enhance understanding of immune system functionality in transplant recipients during the ongoing pandemic.

03 Infectious Disease Surveillance

Comprehensive monitoring of neutralizing antibodies against emerging viral variants, with particular attention to vulnerable populations in Belgium.

  • Variant Tracking
  • Population Immunity Levels
  • Long-term Surveillance

This multi-center study contributes to understanding the evolution of viral immunity across different patient groups.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.